PAN-301-1

February 5, 2018

Panacea Completes Patient Enrollment in Phase 1 Trial of Prostate Cancer Vaccine

News

Panacea Pharmaceuticals has completed patient enrollment in a Phase 1 clinical trial testing its PAN-301-1 vaccine as a treatment for prostate cancer that has failed to respond to other therapies. The multi-center trial (NCT03120832) ... Read more

January 19, 2017January 19, 2017

Phase 1 Trial Begins for Immunotherapy Vaccine for Persistent Prostate Cancers

News

An open-label, multicenter Phase 1 clinical trial has begun to evaluate the safety and immunogenicity of Panacea Pharmaceuticals’ PAN-301-1, a nanoparticle immunotherapy vaccine that targets HAAH-positive cancer cells in patients ... Read more